Profil
Karen Callewaert currently holds the position of Treasurer & Vice President at Oxford Biomedical Research, Inc. Her current job is still at Oxford Biomedical Research, Inc.
Aktive Positionen von Karen Callewaert
Unternehmen | Position | Beginn |
---|---|---|
Oxford Biomedical Research, Inc.
Oxford Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Oxford Biomedical Research (OBR) develops, manufactures and markets assay kits, recombinant proteins and antibodies for biomedical research and drug discovery. The company's primary focus is on the identification and assay of biomarkers for oxidative stress and chronic inflammation, two major risk factors for multiple diseases. OBR is employing proprietary technology to develop tissue and disease specific biomarkers. ProteoMine™ is a cost effective tool for removing high abundance proteins for biomarker discovery. ToxProfiler™ technology captures and detects oxidized proteins in blood correlated with organ-specific toxicity and disease. New platform technologies such as Toxic proteomics and Metabolomics are being applied, adapted and modified into new and practical ways for the diagnosis of early onset disease and for the prevention of diseases. The company was founded in 1984 and is headquartered in Rochester Hills, MI. | Treasurer | 17.05.2011 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Oxford Biomedical Research, Inc.
Oxford Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Oxford Biomedical Research (OBR) develops, manufactures and markets assay kits, recombinant proteins and antibodies for biomedical research and drug discovery. The company's primary focus is on the identification and assay of biomarkers for oxidative stress and chronic inflammation, two major risk factors for multiple diseases. OBR is employing proprietary technology to develop tissue and disease specific biomarkers. ProteoMine™ is a cost effective tool for removing high abundance proteins for biomarker discovery. ToxProfiler™ technology captures and detects oxidized proteins in blood correlated with organ-specific toxicity and disease. New platform technologies such as Toxic proteomics and Metabolomics are being applied, adapted and modified into new and practical ways for the diagnosis of early onset disease and for the prevention of diseases. The company was founded in 1984 and is headquartered in Rochester Hills, MI. | Commercial Services |